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Abstract
Pathogen reduction technology (PRT) has been developed in an effort to make the blood
supply safer, but there is controversy as to whether it may induce structural or functional
changes to platelets that could lead to acute lung injury after transfusion. In this study, we
used a commercial PRT system to treat human platelets that were then transfused into
immunodeficient mice, and the development of acute lung injury was determined. P-selectin
expression was higher in the Mirasol PRT-treated platelets compared to control platelets on
storage day 5, but not storage day 1. Transfusion of control vs. Mirasol PRT-treated plate-
lets (day 5 of storage, 109 platelets per mouse) into NOD/SCID mice did not result in lung
injury, however transfusion of storage day 5 platelets treated with thrombin receptor-activat-
ing peptide increased both extravascular lung water and lung vascular permeability. Trans-
fusion of day 1 platelets did not produce lung injury in any group, and LPS priming 24 hours
before transfusion had no effect on lung injury. In a model of transfusion-related acute lung
injury, NOD/SCID mice were susceptible to acute lung injury when challenged with H-2Kd
monoclonal antibody vs. isotype control antibody. Using lung intravital microscopy, we did
not detect a difference in the dynamic retention of platelets in the lung circulation in control
vs. Mirasol PRT-treated groups. In conclusion, Mirasol PRT produced an increase in P-
selectin expression that is storage-dependent, but transfusion of human platelets treated
with Mirasol PRT into immunodeficient mice did not result in greater platelet retention in the
lungs or the development of acute lung injury.
Introduction
The safety of the blood supply has progressively improved since the advent of modern transfu-
sion therapy in the first half of the 20th century. The use of nucleic acid amplification testing
for hepatitis B, hepatitis C, and the human immunodeficiency virus have substantially reduced
the transmission risk to 1:1–10 million [1]. However, substantial residual risk of transmission
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remains for known and emerging bacterial, viral, and parasitic infections that can have devas-
tating consequences to the recipient. Platelets are particularly a concern for the transmission
of bacterial infections, since platelets are stored at room temperature prior to transfusion.
Another concern is the transfusion of fresh, warm whole blood in the military when there is
not enough time or resources to screen the blood for pathogens [2].
To address this problem, there have been a variety of pathogen-reduction technologies
(PRT) that have been developed to deactivate pathogens prior to transfusion therapy [3]. These
technologies efficiently target possible pathogens, but there is concern that donor cells (red
blood cells, platelets) can be damaged in the process. In a prospective study in which human
platelet units were treated with a psoralen-based PRT, there was an excess of patients in the
PRT arm that developed the acute respiratory distress syndrome, which potentially could be
related to PRT-induced platelet activation [4]. Indeed, platelets have been implicated in experi-
mental transfusion-related acute lung injury (TRALI) as critical mediators, along with neutro-
phils, of lung barrier disruption [5–7]. Platelets are armed with a variety of mediators that
could potentially injure the lung barrier, and platelets may also “partner” with other leukocytes
(neutrophils, monocytes) to enhance inflammatory responses [8].
In this study, we tested a PRT based on the addition of a photosensitizing agent, (riboflavin,
vitamin B2), to human platelet units followed by ultraviolet light illumination [9]. This process
creates chromosomal strand breakage, which effectively renders a variety of pathogens inactive.
We tested whether Mirasol PRT activates human platelets and whether these platelets, when
transfused into immunodeficient mice, induces lung injury. We also tested whether platelets
treated with Mirasol PRT accumulate in the lungs after transfusion. Our results indicate that
Mirasol PRT produces platelet activation during storage, but the platelet activation does not
lead to greater retention in the lungs or the development of lung injury.
Materials and Methods
Mice
NOD/SCID mice (Jackson Laboratories) at 6–10 weeks of age were used for all experiments.
All mice were housed in pathogen-free conditions.
Ethics Statement
Blood was purchased from the Blood Centers of the Pacific (San Francisco, CA) and the
authors had no contact with the blood donors. Therefore, this study does not involve human
subjects research. The study was carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use Committee at the University
of California, San Francisco (Protocol #AN099492). All surgery was performed under ketamine
and xylazine anesthesia, and all efforts were made to minimize suffering.
Human platelet collection and Mirasol PRT treatment
Human, apheresis double dose platelet concentrates were collected from the Blood Centers of
the Pacific (San Francisco, CA) in the afternoon in ACDA using a Trima collection device
(Terumo BCT, USA), with a target yield of 5.5–7.0 x 1011 platelets/unit. Platelets were stored
overnight on platelet agitators in a temperature-controlled room. The following morning, half
of the volume of each product was transferred to a Mirasol Illumination Bag (MIB) while the
other half remained in the collection bag. Thirty-five (35) mL of 500 μM riboflavin solution
was added to the test units for treatment with the Mirasol system, and these products received
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a UV energy dose of 6.24 J/mL. To mimic the dilution of the test products with riboflavin, 35
mL of normal saline was added to the untreated control products. All products were stored
under standard blood banking conditions until the time of analysis.
Mouse model and acute lung injury measurements
NOD/SCID mice were anesthetized with ketamine and xylazine and human platelets were
transfused via the jugular vein. The following conditions were tested: 108 platelets (untreated
control vs. Mirasol PRT) on days 1 and 5 of storage, 109 platelets (control vs. Mirasol PRT) on
days 1 and 5 of storage, and LPS (Escherichia coli O55:B5; Sigma-Aldrich) priming (0.1 mg/kg,
i.p., 24 hours prior) followed by 108 platelets (control vs. Mirasol PRT) on days 1 and 5 of stor-
age, and LPS priming (0.1 mg/kg, i.p., 24 hours prior) followed by 109 platelets (control vs.
Mirasol PRT) on days 1 and 5 of storage. We also test thrombin-receptor activating peptide
(TRAP) stimulated platelets by incubating platelets with TRAP (50 μM) for 10 minutes prior
to transfusion. At 4 hours after transfusion, mice were euthanized and the blood and lungs col-
lected for acute lung injury measurements. We measured extravascular lung water using the
gravimetric method and lung vascular permeability by injecting mice with 125I-albumin (Iso-
Tex Diagnostics) in the jugular vein at the time of transfusion and measuring the extravasation
of the radiolabeled albumin into the bloodless lung using a gamma counter (Packard 5000
Series) [7].
TRALI model
A two-event TRALI model was used, as previously described [6]. Briefly, after being primed
with LPS (0.1 mg/kg, i.p.) for 24 hours, NOD/SCID mice were challenged with a mouse MHC I
mAb (ATCC 34-1-2S; H2Kd; IgG2a, κ; 1.0 mg/kg) vs. isotype control mAb (BD Biosciences;
Cat. 553453) injected into the jugular vein, and euthanized after 2 hours. Extravascular lung
water and lung vascular permeability were measured.
Flow cytometry
Reagents were purchased from BD Biosciences. Platelets were identified by human glycopro-
tein IIb surface staining (CD41a-PE; IgG1, κ; Cat. 555467). Platelet activation was determined
by P-selectin expression (CD62P-APC; IgG1, κ; Cat. 550888) on CD41+ events. All antibodies
were used at optimum concentration for maximum fluorescence with minimum nonspecific
binding, as described by the manufacturer. Platelets (100 μL) were prepared for flow cytometric
analysis by adding 20μL of CD41a or CD62P antibodies and gently mixing. The samples were
incubated for 60 minutes, and then diluted with 1 mL of BD PhosFlow Lyse/Fix Buffer (Cat.
558049) to fix, lyse the red cells, and inhibit further activation of the platelets. Incubations were
carried out at room temperature (20 to 22°C) in the dark, and all samples were run in duplicate.
Fifty thousand platelets were analyzed, and the results represent the means of duplicate sam-
ples. Samples were analyzed, within 2 hours of collection with a LSRII/Fortessa flow cytometer
(BD Biosciences). The platelet population was identified from its light scatter characteristics
and confirmed using the anti-CD41a mAb. All data were analyzed using FlowJo software
(TreeStar).
Lung intravital microscopy
We used two-photon microscopy adapted for the ventilated mouse lung to track human plate-
lets in the lung after transfusion [10]. Briefly, human platelets (control vs. Mirasol PRT) on
storage days 1 and 5 were fluorescently labeled using a CellTrace CFSE Cell Proliferation kit
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(Life Technologies) according the manufacturer’s instructions and washed prior to transfusion
(109) into anesthetized, mechanically ventilated NOD/SCID mice ± LPS priming. CFSE-labeled
platelets were excited with a two-photon laser tuned to 820 nm. We captured a 210 μm x
210 μm (0.05 mm2) area of lung at 10 μm z-depth and images were captured every 1 second for
10 minutes. Images were analyzed with Imaris 7.6.1 software (Bitplane), and CFSE+ events
were counted at 10 minutes post-injection in the treatment groups.
Statistical analysis
Results are reported as mean ± SD. To determine significance, 2-tailed Student’s t and ANOVA
tests were used as appropriate (GraphPad PRISM version 5.0). P values of less than or equal to
0.05 were deemed to be significant.
Results
Mirasol PRT treatment of human platelets increases surface expression
of P-selectin
We tested whether Mirasol PRT-treatment of human platelets induces activation by testing for
surface P-selectin (CD62P) expression by flow cytometry. Platelets were identified by CD41a
expression and reported as the %CD62+/CD41+ events. There was trend (p = 0.16) for
increased P-selectin expression in the Mirasol PRT group on day 1 of storage (Fig 1). On day 5
of storage, platelets treated with Mirasol PRT had increased expression of CD62P (Fig 1).
NOD/SCID mice develop lung injury in a two-event model of TRALI
We first tested if NOD/SCID mice were able to develop lung injury in a two-event model of
TRALI. NOD/SCID mice have the H-2Kd haplotype and thus should be susceptible to cognate
H2Kd mAb. NOD/SCID mice also have normal numbers of circulating neutrophils and plate-
lets, which are critical effector cells in producing lung injury. NOD/SCID mice were challenged
with 1 mg/kg of H2Kd mAb vs. isotype control mAb and the H2Kd mAb group had significant
increases in extravascular lung water and lung vascular permeability, indicative of acute lung
injury (Fig 2). We did not observe any mortality at 2 hours post-Ab injection.
Transfusion of Mirasol PRT-treated platelets or control platelets does not
produce acute lung injury
Having determined that NOD/SCID mice were capable of developing TRALI, we next chal-
lenged mice with control vs. Mirasol PRT platelet transfusions on storage days 1 and 5. We
tested two doses of platelets: 108 and 109 per mouse. As a positive control, we added TRAP
(50 μM) to untreated platelets 10 minutes prior to transfusion. In Fig 3, transfusion of TRAP-
stimulated platelets (109) on storage day 5 produced significant increases in both extravascular
lung water and lung vascular permeability, similar to that observed in the H2Kd mAb group in
Fig 2. We did not detect any differences in lung injury measurements in control or Mirasol
PRT platelets transfused on storage days 1 or 5 (Fig 3), and in general, lung injury measure-
ments after control or Mirasol PRT platelet transfusions were not significantly different than
the LPS + isotype control mAb group in Fig 2. We also did not detect significant increases in
lung injury in either the control or Mirasol PRT platelets when transfused at 108 platelets/
mouse (data not shown).
Pathogen Reduction Technology and Lung Injury
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Transfusion of Mirasol PRT-treated platelets or control platelets does not
produce acute lung injury in a two-event model with LPS
Since experimental and clinical transfusion-related acute lung injury (TRALI) involves a two-
event hypothesis in which immune priming factors in the transfusion recipient are necessary
to produce lung injury [6], we next challenged mice with intraperitoneal LPS (0.1 mg/kg) 24
Fig 1. Platelet activation in control and Mirasol PRT-treated human platelets. P-selectin (CD62P)
expression by human platelets on storage days 1 and 5 ±Mirasol PRT. *p<0.05 vs. day 5 control. n = 4–6 per
group. Mean ± SD.
doi:10.1371/journal.pone.0133022.g001
Fig 2. Lung injury in LPS-primed NOD/SCIDmice challenged with H-2KdmAb. A. Extravascular lung
water in LPS-primed (0.1 mg/kg i.p.) NOD/SCID mice challenged with H2Kd mAb (1 mg/kg, i.v.) vs. isotype
control mAb. B. Lung vascular permeability to 125I-albumin (i.v.) in LPS-primed (0.1 mg/kg i.p.) NOD/SCID
mice challenged with H2Kd mAb (1 mg/kg, i.v.) vs. isotype control mAb. *p<0.05 vs. LPS + isotype control
mAb groups. Mean ± SD. n = 5 per group.
doi:10.1371/journal.pone.0133022.g002
Pathogen Reduction Technology and Lung Injury
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hours prior to human platelet transfusion. In Fig 4, LPS priming did not augment lung injury
in any of the groups (control, Mirasol PRT, TRAP) compared to lung injury measurements in
Fig 3. Lung injury measurements in control and Mirasol PRT groups were similar to measure-
ments in the LPS + isotype control mAb group in Fig 2.
Fig 3. Lung injury in control, Mirasol PRT, and TRAP-treated human platelets transfused into NOD/SCIDmice. A. Extravascular lung water in NOD/
SCID mice transfused with 109 human platelets (control vs. Mirasol PRT vs. TRAP-activated) on day 1 or day 5 of storage.B. Lung vascular permeability to
125I-albumin (i.v.) in NOD/SCID mice transfused with 109 human platelets (control vs. Mirasol PRT vs. TRAP-activated) on day 1 or day 5 of storage. *p<0.05
vs. day 5 control and Mirasol PRT groups. TRAP = thrombin receptor activating peptide (50 μM). Mean ± SD. n = 5 per group.
doi:10.1371/journal.pone.0133022.g003
Pathogen Reduction Technology and Lung Injury
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Fig 4. Lung injury in control, Mirasol PRT, and TRAP-treated human platelets transfused into LPS-primed NOD/SCID mice. A. Extravascular lung
water in LPS-primed (0.1 mg/kg i.p.) NOD/SCID mice transfused with 108 human platelets (control vs. Mirasol PRT vs. TRAP-activated) on day 1 or day 5 of
storage.B. Lung vascular permeability to 125I-albumin (i.v.) in LPS-primed (0.1 mg/kg i.p.) NOD/SCID mice transfused with 108 human platelets (control vs.
Mirasol PRT vs. TRAP-activated) on day 1 or day 5 of storage. Mean ± SD. n = 5 per group.
doi:10.1371/journal.pone.0133022.g004
Pathogen Reduction Technology and Lung Injury
PLOS ONE | DOI:10.1371/journal.pone.0133022 July 15, 2015 7 / 11
Transfused Mirasol PRT-treated platelets are not differentially retained
in the lungs vs. control platelets
We next tested whether control or Mirasol PRT platelets on storage days 1 or 5 are differen-
tially retained in the pulmonary circulation after transfusion. We used two-photon intravital
lung microscopy and CFSE-labeled platelets transfused via the jugular vein and captured
images every second for 10 minutes. In Fig 5A–5C, a representative example is shown in which
we transfused 109 CFSE-labeled control platelets (day 5 of storage) into unprimed NOD/SCID
mice and screenshots are shown at 30 sec (A), 1min (B), and 5min (C) post-transfusion (see
also S1 Movie). A representative example is shown in Fig 5D–5F fromMirasol PRT-treated
platelets (109, day 5 of storage) transfused into unprimed NOD/SCID mice (see also S2 Movie).
The blue color in Fig 5 and the S1 and S2 Movies is collagen’s second harmonic generation,
which aids in visualizing the alveolar structure of the lung. For our analysis, we counted the
number of platelets remaining at 10 minutes post-transfusion and divided by the maximum
number of platelets imaged during any frame in the 10 minute movie. We did not detect any
differences in day 1 and day 5 platelet retention and therefore combined these groups in our
analysis. In general, the majority of transfused platelets had exited the visualized lung microcir-
culation at 10 minutes post-transfusion, but 20–40% remained (Fig 5G). However, we did not
detect any statistically significant differences in the retention rate of platelets between the
groups (Fig 5G).
Discussion
The major findings from this study are (1) Mirasol PRT treatment of human platelets produces
platelet activation that is storage-dependent, (2) NOD/SCID, despite major deficits in cellular
and humoral immunity, are susceptible to a two-event model of TRALI, (3) transfusion of con-
trol or Mirasol PRT human platelets into NOD/SCID mice, even at high doses and with LPS
priming, does not produce significant acute lung injury or differential retention in the lung
microcirculation.
PRT has the potential to improve the safety of the blood supply and may be especially useful
in resource-limited settings, such as the military theatre, where sophisticated molecular screen-
ing for blood-borne pathogens is not feasible. However, it is imperative that non-infectious
transfusion complications not be increased by the transfusion of PRT-treated products. One
such concern is the development of acute lung injury (ALI) or the acute respiratory distress
syndrome (ARDS), which in one clinical study was increased in the psoralen-based PRT-
treated platelet product group [4]. The potential association of PRT-treated products with ALI
is a serious safety concern, and in this study we designed pre-clinical experiments to determine
whether a specific form of PRT, Mirasol PRT, applied to human platelets led to the develop-
ment of lung injury.
We detected that human platelets treated with Mirasol PRT have evidence of activation that
was storage dependent. Others have also reported similar findings on platelet activation with
Mirasol PRT [11]. P-selectin expression, in particular, is not just a marker of activated platelets,
but could mediate critical interactions with leukocytes that express its ligand, PSGL-1, and
therefore could drive inflammatory responses after transfusion [12]. However, despite evidence
of platelet activation with Mirasol PRT, when these platelets were transfused into immunode-
ficient mice and tracked using two-photon intravital lung microscopy, we did not detect an
increased retention rate compared to control platelets. Further, transfusion of Mirasol PRT-
treated platelets did not result in lung injury even with recipient priming with LPS and with the
delivery of high concentrations of platelets. We tested two doses of platelet transfusions, 108
Pathogen Reduction Technology and Lung Injury
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and 109, and the latter dose represents approximately>50% of the total native mouse platelet
circulating pool, which is a significant challenge.
NOD/SCID mice were chosen as the transfusion recipients in this study, since we were
transfusing human platelets and the defects in humoral and cellular immunity in these mice
make them appropriate recipients [13]. We tested whether the residual components of the
immune system of NOD/SCID mice (neutrophils, NK cells, platelets) would be sufficient to
produce lung injury. We chose a neutrophil- and platelet-dependent model of antibody-medi-
ated transfusion-related acute lung injury (TRALI), and indeed the NOD/SCIDmice developed
lung injury, although the magnitude of injury is less than in wild-type mice [6]. This is likely
due to the mixed MHC Class I background of these mice (less cognate H-2Kd antigen) com-
pared with BALB/c wild-type mice (pure H-2Kd). NOD/SCID mice also developed lung injury
Fig 5. Real-time lung imaging of human platelets in the lungs of NOD/SCIDmice. Lung intravital
microscopy in unprimed NOD/SCID mice transfused with CFSE-labeled control (A-C) or Mirasol-PRT
platelets (D-F) both on storage day 5 (109 platelets). Images were captured every second for 10 minutes and
screenshots are shown from 30 sec, 1 min, and 5 min post-transfusion. Scale bar = 50 μm. (G) %Platelets
remaining in the imaged lung@ 10minutes post-transfusion (# at 10 min/maximum #) in NOD/SCID
mice ± LPS priming + Control vs. Mirasol PRT-treated platelets.
doi:10.1371/journal.pone.0133022.g005
Pathogen Reduction Technology and Lung Injury
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when challenged with TRAP-activated platelets, so we conclude that lung injury can be studied
in this mouse model. Others have reported that SCID mice, which are similar, but less immu-
nodeficient than NOD/SCID mice, are also susceptible to TRALI [14, 15].
Our results are consistent with recently published results using Mirasol PRT-treated human
platelets transfused into SCID recipients, which did not result in either increased lung accumu-
lation or the development of lung injury [15]. Only when the PRT treatment (illumination)
was repeated multiple times on the same platelet product was there an increase in platelet accu-
mulation in the lungs [15]. Notably, when human platelets were treated with high-dose UVB
irradiation alone and transfused into LPS-primed SCID mice, platelet accumulation in the
lungs and lung injury were observed [16, 17]. However, the dose of UVB irradiation that was
studied is not used in commercial PRT systems, and therefore these results have uncertain clin-
ical relevance.
Our study has limitations. Our studies do not directly compare to the transfusion conditions
in humans. Although the blood collection and Mirasol PRT treatment were done using clinical
protocols, we transfused the platelets into immunodeficient mice with normal platelet counts,
which does not mimic the majority of transfusion recipients. Also, our study was limited to 4
hours after transfusion, and therefore longer-term complications of platelet transfusion were
not studied. However, lung injury developed within 4 hours in both the TRALI model and with
TRAP-activated platelets, so we believe it is unlikely that delayed lung injury was missed.
In conclusion, although Mirasol PRT-treatment of human platelets produces storage-
dependent platelet activation, when these platelets were transfused at a high dose into LPS-
primed mice, we did not observe increased sequestration in the lung microcirculation or the
development of lung injury. These data do not support an adverse pulmonary reaction to the
transfusion of PRT-treated platelets and is important safety data for the clinical development
of PRT technology.
Supporting Information
S1 Movie. Two photon lung intravital imaging in an unprimed NOD/SCID mouse trans-
fused with CFSE-labeled control platelets (109, storage day 5) and imaged every second for
5 minutes. x, y, z dimensions 210 μm, 210 μm, and 10 μm, respectively. Scale bar = 50 μm.
(AVI)
S2 Movie. Two photon lung intravital imaging in an unprimed NOD/SCID mouse trans-
fused with CFSE-labeled Mirasol-PRT platelets (109, storage day 5) and imaged every sec-
ond for 5 minutes. x, y, z dimensions 210 μm, 210 μm, and 10 μm, respectively. Scale
bar = 50 μm.
(AVI)
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